Repligen (NASDAQ:RGEN) Price Target Cut to $130.00 by Analysts at Evercore ISI

Repligen (NASDAQ:RGEN - Get Free Report) had its price objective lowered by research analysts at Evercore ISI from $140.00 to $130.00 in a research note issued on Tuesday,Benzinga reports. The firm presently has an "in-line" rating on the biotechnology company's stock. Evercore ISI's price objective points to a potential upside of 0.53% from the company's current price.

A number of other research firms have also commented on RGEN. JPMorgan Chase & Co. lowered their price target on Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a research report on Tuesday, April 29th. HC Wainwright reissued a "buy" rating and issued a $180.00 price target on shares of Repligen in a research report on Monday, May 5th. Canaccord Genuity Group lowered their price target on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research report on Wednesday, April 16th. Royal Bank Of Canada decreased their target price on Repligen from $202.00 to $189.00 and set an "outperform" rating for the company in a research report on Wednesday, April 30th. Finally, Wolfe Research raised Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 target price for the company in a research report on Tuesday, April 29th. Five investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $170.75.

Repligen Trading Up 0.6%

Shares of Repligen stock traded up $0.76 on Tuesday, reaching $129.32. 252,751 shares of the company's stock were exchanged, compared to its average volume of 725,949. The company has a market capitalization of $7.27 billion, a P/E ratio of -286.16, a price-to-earnings-growth ratio of 3.56 and a beta of 1.11. Repligen has a 52 week low of $102.97 and a 52 week high of $182.52. The firm's 50-day moving average is $126.10 and its two-hundred day moving average is $139.65. The company has a debt-to-equity ratio of 0.27, a quick ratio of 5.79 and a current ratio of 6.79.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.35 by $0.04. Repligen had a positive return on equity of 4.53% and a negative net margin of 3.93%. The company had revenue of $169.17 million for the quarter, compared to analysts' expectations of $163.65 million. During the same period last year, the business earned $0.28 EPS. Repligen's quarterly revenue was up 10.4% compared to the same quarter last year. Sell-side analysts predict that Repligen will post 1.72 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Signaturefd LLC boosted its stake in Repligen by 172.2% in the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 124 shares during the period. Sava Infond d.o.o. bought a new stake in shares of Repligen during the 4th quarter valued at about $29,000. Raiffeisen Bank International AG bought a new stake in shares of Repligen during the 4th quarter valued at about $29,000. Twin Tree Management LP bought a new stake in shares of Repligen during the 1st quarter valued at about $29,000. Finally, Itau Unibanco Holding S.A. bought a new stake in shares of Repligen during the 4th quarter valued at about $40,000. Institutional investors own 97.64% of the company's stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.